Voices call for a healthcare paradigm shift toward personalized medicine. What does the approval of Vanda's Fanapt teach contenders in this space? What hobbles the paradigm shift? Drug development is stymied by a variety of factors. How is the FDA transforming to facilitate R&D? How are scrutiny and regulation of the industry changing in major-market regions? What are the opportunities in niche diseases? Novo Nordisk took a big step in the social marketing arena with the launch of a Twitter-based campaign. How is the company using this medium? How does the campaign relate to conventional marketing wisdom? What are the related regulatory issues? Pharma industry dealmaking continues at a relatively steady state. What companies are among the big players? What are the notable deals of the second quarter of 2009? How has the H1N1 flu pandemic influenced dealmaking? National governments have enacted measures to drive use of generics and biosimilars. What results have been recorded in the United States? In Japan? What effect has this focus had on the fortunes of generics companies?

researchandmarkets